Lesson plan

ecromeximab

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of melanoma. The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.

Back to article

Article summary

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of melanoma. The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.